论文部分内容阅读
[目的]观察疏肝健脾法联合行为干预治疗非酒精性脂肪性肝病患者的临床疗效。[方法]将92非酒精性脂肪性肝病患者随机分为观察组47例,对照组45例;观察组采用疏肝健脾方药联合行为干预治疗;对照组采用比格列酮联合行为干预治疗,共治疗3个月。观察2组患者治疗前后肝功能(ALT、AST)、血脂(TG、TC)等指标,计算体质量指数(BMI)、腰臀比(WHR)、胰岛素抵抗指数(HOMA-IR),比较2组患者治疗前后中医证候积分、B超改善情况。[结果]2组患者治疗后BMI、WHR、ALT、TG、TC均较治疗前下降,组间比较差异无统计学意义;治疗后2组中医证候积分、B超较治疗前下降,观察组低于对照组(P<0.05);观察组HOMA-IR低于对照组(P<0.05);观察组总有效率为87.23%,对照组71.11%,差异有显著性意义(P<0.05)。[结论]疏肝健脾方药联合行为干预治疗非酒精性脂肪性肝病可明显改善患者肝功能、降低血脂水平,提高患者生活质量。
[Objective] To observe the clinical effect of Shuganjianpi combined with behavioral intervention on patients with non-alcoholic fatty liver disease. [Methods] Ninety-two non-alcoholic fatty liver disease patients were randomly divided into observation group (n = 47) and control group (n = 45). The observation group was treated with Shuganjianpi Decoction combined with behavioral intervention. A total of 3 months treatment. The indexes of liver function (ALT, AST), blood lipid (TG, TC) before and after treatment were observed and the body mass index (BMI), WHR and HOMA-IR were calculated. Before and after treatment of patients with TCM syndrome score, B-ultrasound to improve the situation. [Results] After treatment, the BMI, WHR, ALT, TG and TC in two groups decreased compared with those before treatment, and there was no significant difference between the two groups. After treatment, the score of TCM syndrome, (P <0.05). The HOMA-IR in the observation group was lower than that in the control group (P <0.05). The total effective rate was 87.23% in the observation group and 71.11% in the control group, with significant difference (P <0.05). [Conclusion] Shuganjianpi Decoction combined with behavioral intervention in the treatment of non-alcoholic fatty liver disease can significantly improve liver function, reduce blood lipid levels and improve the quality of life of patients.